

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a BTK antagonist, an anti-ROR-1 antibody, and a pharmaceutically acceptable excipient, wherein said anti-ROR-1 antibody comprises a humanized heavy chain variable region and a humanized light chain variable region, wherein said humanized heavy chain variable region comprises the sequences set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and wherein said humanized light chain variable region comprises the sequences set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
2. The pharmaceutical composition of claim 1, wherein said BTK antagonist and said anti-ROR-1 antibody are present in a combined synergistic amount, wherein said combined synergistic amount is effective to treat an ROR-1 expressing cancer or a cancer susceptible to a BTK antagonist in a subject in need thereof.
3. The pharmaceutical composition of claim 1, wherein said BTK antagonist is a small molecule.
4. The pharmaceutical composition of claim 1, wherein said BTK antagonist is ibrutinib, acalabrutinib, ONO/GS-4059, BGB-3111 or CC-292 (AVL-292).
5. The pharmaceutical composition of claim 1, wherein said BTK antagonist is ibrutinib.
6. The pharmaceutical composition of claim 1, wherein said anti-ROR-1 antibody is cirmtuzumab.
7. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for treating an ROR-1 expressing cancer or a cancer susceptible to a BTK antagonist in a subject in need thereof.

8. The use of claim 7, wherein said BTK antagonist is a small molecule.
9. The use of claim 7, wherein said BTK antagonist comprises ibrutinib, acalabrutinib, ONO/GS-4059, BGB-3111, or CC-292 (AVL-292).
10. The use of claim 7, wherein said BTK antagonist is ibrutinib.
11. The use of claim 7, wherein said anti-ROR-1 antibody is cirmtuzumab.
12. The use of claim 7, wherein said BTK antagonist and said anti-ROR-1 antibody are to be administered in a combined synergistic amount.
13. The use of claim 7, wherein said BTK antagonist and said anti-ROR-1 antibody are admixed prior to administration.
14. The use of claim 7, wherein said BTK antagonist is to be administered at an amount of about 1 mg/kg, 2 mg/kg, 5 mg/kg, 10 mg/kg or 15 mg/kg.
15. The use of claim 7, wherein said BTK antagonist is to be administered at an amount of about 5 mg/kg.
16. The use of claim 7, wherein said BTK antagonist is to be administered at an amount of about 420 mg.
17. The use of claim 7, wherein said anti-ROR-1 antibody is to be administered at an amount of about 1 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg or 10 mg/kg.
18. The use of claim 7, wherein said anti-ROR-1 antibody is to be administered at an amount of about 2 mg/kg.
19. The use of claim 7, wherein said BTK antagonist is to be administered at an amount of about 5 mg/kg and said anti-ROR-1 antibody is to be administered at about 2 mg/kg.

20. The use of claim 7, wherein said BTK antagonist is to be administered at an amount of about 5 mg/kg and said anti-ROR-1 antibody is to be administered at about 1 mg/kg.
21. The use of claim 7, wherein the pharmaceutical composition is to be administered intravenously.
22. The use of claim 7, wherein said subject is a mammal.
23. The use of claim 7, wherein said subject is a human.
24. The use of claim 7, wherein said ROR-1 expressing cancer or said cancer susceptible to a BTK antagonist is lymphoma, leukemia, myeloma, AML, B-ALL, T-ALL, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, epithelial squamous cell cancer, melanoma, stomach cancer, brain cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, head and neck cancer, uterine cancer, adenocarcinoma, or adrenal cancer.
25. The use of claim 7, wherein said ROR-1 expressing cancer or said cancer susceptible to a BTK antagonist is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, marginal cell B-Cell lymphoma, Burkitt's Lymphoma, or B cell leukemia.